Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.

Biopharma R&D: Alnylam vs. Arrowhead's Decade of Growth

__timestampAlnylam Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.
Wednesday, January 1, 201419024900023138050
Thursday, January 1, 201527649500057410147
Friday, January 1, 201638239200041454452
Sunday, January 1, 201739063500031690298
Monday, January 1, 201850542000052968505
Tuesday, January 1, 201965511400081048686
Wednesday, January 1, 2020654819000128874979
Friday, January 1, 2021792156000206342000
Saturday, January 1, 2022883015000297307000
Sunday, January 1, 20231004415000353188000
Monday, January 1, 20241126232000505870000
Loading chart...

Cracking the code

A Decade of Innovation: R&D Investments in Biopharmaceuticals

In the competitive world of biopharmaceuticals, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Alnylam Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated significant commitment to R&D, albeit at different scales. Alnylam's R&D expenses have surged by over 400% from 2014 to 2023, reflecting its aggressive pursuit of cutting-edge therapies. In contrast, Arrowhead has shown a remarkable 1,400% increase in the same period, albeit from a smaller base, highlighting its rapid growth trajectory.

Key Insights

  • Alnylam Pharmaceuticals: By 2023, Alnylam's R&D spending reached its peak, underscoring its leadership in RNA interference therapeutics.
  • Arrowhead Pharmaceuticals: Despite starting with lower R&D expenses, Arrowhead's consistent growth indicates its expanding pipeline in RNAi and gene therapy.

The data for 2024 is incomplete, suggesting ongoing developments in both companies' R&D strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025